Martin Kohlhäeufl

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

Leora Horn, David R. Spigel, Everett E. Vokes et al. · Journal of Clinical Oncology · 2017 · 875 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).

Luis Paz‐Ares, Leora Horn, Hossein Borghaei et al. · Journal of Clinical Oncology · 2015 · 147 citations

Medicine, Oncology, Pharmacotherapy +11

Phase II Trial of a Trimodality Regimen for Stage III Non–Small-Cell Lung Cancer Using Chemotherapy As Induction Treatment With Concurrent Hyperfractionated Chemoradiation With Carboplatin and Paclitaxel Followed by Subsequent Resection: A Single-Center Study

Godehard Friedel, Wilfried Budach, Juergen Dippon et al. · Journal of Clinical Oncology · 2010 · 77 citations · Full text

Medicine, Oncology, Surgery +17

Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis

Francesco Bonella, Michael Kreuter, Lars Hagmeyer et al. · Respiration · 2016 · 66 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets)

Jonathan W. Goldman, Lucio Crinò, Everett E. Vokes et al. · Journal of Thoracic Oncology · 2016 · 42 citations

Medicine, Neurology, Oncology +11